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Chromosomal translocations involving transcription factor genes have been identified in an increasingly wide range of
cancers. Some translocations can create a protein ‘‘chimera’’ that is composed of parts from different proteins. How such
chimeras cause cancer, and why they cause cancer in some cell types but not others, is not understood. One such chimera
is EWS–FLI, the most frequently occurring translocation in Ewing Sarcoma, a malignant bone and soft tissue tumor of
children and young adults. Using EWS–FLI and its parental transcription factor, FLI1, we created a unique experimental
system to address questions regarding the genomic mechanisms by which chimeric transcription factors cause cancer. We
found that in tumor cells, EWS–FLI targets regions of the genome distinct from FLI1, despite identical DNA-binding
domains. In primary endothelial cells, however, EWS–FLI and FLI1 demonstrate similar targeting. To understand this
mistargeting, we examined chromatin organization. Regions targeted by EWS–FLI are normally repressed and nucleo-
somal in primary endothelial cells. In tumor cells, however, bound regions are nucleosome depleted and harbor the
chromatin signature of enhancers. We next demonstrated that through chimerism, EWS–FLI acquired the ability to alter
chromatin. Expression of EWS–FLI results in nucleosome depletion at targeted sites, whereas silencing of EWS–FLI in
tumor cells restored nucleosome occupancy. Thus, the EWS–FLI chimera acquired chromatin-altering activity, leading to
mistargeting, chromatin disruption, and ultimately, transcriptional dysregulation.
[Supplemental material is available for this article.]
Recurrent chromosomal translocations have been associated with
an increasingly wide range of human cancers. Commonly involving
genes encoding transcriptional regulators, translocations can de-
regulate gene expression and generate structurally novel oncogenic
fusion proteins (Bernheim 2010). The transforming activity of these
chimeric genes typically reveals cell type specificity, suggesting that
certain developmental lineages are permissive for transformation.
Studies of oncogenic transcription factors have typically focused only
on the fusion products or their target genes and often in heterologous
cells, limiting insights into the relative influence of chimerism and
cell lineage.
Ewing Sarcoma, a bone tumor of children and young adults, is
characterized by translocations that fuse a member of the TET family
to a member of the ETS transcription factor family (Delattre et al.
1992; Sorensen et al. 1994; Jeon et al. 1995). Identified in 80%–85%
of Ewing Sarcoma, t(11;22)(q24;q12) results in an in-frame fusion of
EWSR1 to FLI1 (Delattre et al. 1992). EWS–FLI has been shown to
be a potent transcriptional modulator critical for transformation
(Kinsey et al. 2006; Smith et al. 2006). Structure-function exper-
iments have demonstrated that the EWSR1 domain contributes
transactivation activity, whereas the FLI1 domain directs DNA
binding, and both are required for transformation (Lessnick et al.
1995; Jaishankar et al. 1999). EWS–FLI mediates oncogenesis by
directly or indirectly regulating genes necessary for transformation.
Despite evidence that EWS–FLI is necessary for transformation, ec-
topic expression of EWS–FLI fails to activate similar genetic programs
or transform most human cell lines, indicating that cell specificity
is a major determinant of EWS–FLI activity (Lessnick et al. 2002;
Miyagawa et al. 2008; Riggi et al. 2008).
FLI1, a member of the ETS family, is an important de-
velopmental transcription factor (Rao et al. 1993). Fli1 deletion in
mice results in embryonic death from hemorrhage associated with
aberrant hematopoiesis and vasculogenesis, supporting a role in
endothelial development (Bartel et al. 2000; Spyropoulos et al.
2000; Liu et al. 2008). Translocations involving ETS members have
been implicated in other cancers, including prostate adenocarci-
noma (Tomlins et al. 2005). The function of EWSR1 is less well un-
derstood; however, reports suggest participation in transcription or
RNA splicing (Ohno et al. 1994; Bertolotti et al. 1998). EWSR1-
deficient mice die prior to weaning and show defects in B-cell
development and meiosis (Li et al. 2007). Other translocations
involving EWSR1 have been identified, resulting in chimeras with
ATF1 and WT1 in Clear Cell Sarcoma and Desmoplastic Small
Round Cell Tumors, respectively (Zucman et al. 1993; Benjamin
et al. 1996; Tomlins et al. 2005).
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To characterize the changes in genomic localization and tran-
scriptional output due to chimerism, we compared EWS–FLI with
FLI1 in Ewing Sarcoma and primary human endothelial cells. We
integrated genomic targeting with gene expression profiling and
found that in tumor cells, EWS–FLI associated with distinct genomic
regions lacking canonical ETS binding sites and activating a set of
genes associated with a transformed phenotype. However, in endo-
thelial cells, genomic targeting and gene regulation were similar to
that of FLI1. We then examined the influence of chromatin on this
differential targeting by analyzing chromatin structure and histone
modifications. We found that in Ewing cells, EWS–FLI-targeted sites
exhibited features characteristic of enhancer elements and were
bound by RNA polymerase II. Moreover, EWS–FLI silencing resulted
in increased nucleosome occupancy of these regions. In endothelial
cells, a subset of these regions, normally associated with repressive
chromatin, became nucleosome depleted upon EWS–FLI expres-
sion. These data establish EWS–FLI as a pioneer factor capable of
inducing and maintaining open chromatin architecture.
Results
Chimerism and cell lineage influence genomic targeting
To compare EWS–FLI with its parental protein FLI1, we developed
a lentiviral delivery approach that permitted concurrent silencing of
endogenous EWS–FLI or FLI1 and expression of an epitope-tagged
version of either EWS–FLI or FLI1 (Fig. 1A). Lentiviral knockdown
replacement was performed in a Ewing Sarcoma tumor-derived cell
line (EWS502) and primary human endothelial cells (HUVEC).
HUVEC were selected as they abundantly express FLI1, and FLI1
has been implicated in endothelial development (Spyropoulos et al.
2000; Pusztaszeri et al. 2006; Liu et al. 2008). Genomic localization
of each protein was examined by chromatin immunoprecipitation,
followed by next-generation sequencing (ChIP-seq) (Supplemental
Table 1). Gene expression was also examined using exon micro-
arrays. The lentiviral knockdown-replacement strategy offered
a number of experimental benefits to facilitate comparative ge-
nomic analyses. First, this approach allowed the direct comparison
of each transcription factor in the same cell type as well across cell
types. Second, despite heterogeneity in viral transduction, the use
of lentivirus enabled the titration of protein expression, permitting
approximation of endogenous protein levels while achieving ef-
ficient knockdown (Fig. 1B). Third, expression of a shRNA directed
to the 39 UTR of FLI1 (able to target both endogenous EWS–FLI and
FLI1, but not the transduced genes that do not contain the 39 UTR) in
all experimental conditions minimized the possibility for detecting
off-target effects. Finally, the use of a common and robust antibody
for chromatin immunoprecipitation circumvented issues of an-
tibody sensitivity, specificity, and antigenic variability, factors that
can complicate downstream comparisons, as recently demonstrated
(Egelhofer et al. 2010).
We examined cell proliferation after EWS–FLI knockdown in the
presence or absence of ectopically expressed EWS–FLI or FLI1. In the
tumor cells, transduced EWS–FLI, but not FLI1, rescued the growth
arrest resulting from endogenous EWS–FLI silencing (Fig. 1C; Sup-
plemental Fig. S1). These data support previous reports indicating the
requirement of EWS–FLI for cell proliferation (May et al. 1993a,b;
Tanaka et al. 1997; Smith et al. 2006). Silencing of FLI1 with or
without ectopic expression of EWS–FLI did not affect the proliferation
of endothelial cells under the conditions tested (data not shown).
Differential activities of EWS–FLI and FLI1 could result from
either of two mechanisms. The transcription factors could target
similar genomic sites due to their common DNA-binding domain,
but vary in their ability to modulate gene expression. Alternatively,
chimerism could result in genomic retargeting and subsequent dif-
ferences in transcriptional regulation. To test these two hypotheses,
we performed ChIP-seq for EWS–FLI and FLI1 in both EWS502 and
HUVEC. Analyzing only high-quality, uniquely aligned reads (Sup-
plemental Table 1), binding sites for each factor were determined
using the Zero Inflated Negative Binomial Algorithm (ZINBA),
a flexible statistical model that adjusts for the effects of GC con-
tent, mapability, and copy-number variation (Rashid et al. 2011). We
identified 7172 and 13,878 EWS–FLI binding sites in EWS502 and
HUVEC, respectively. FLI1 bound 18,958 regions in EWS502 and
39,439 regions in HUVEC (Fig. 2A; Supplemental Table 2). The
greater number of EWS–FLI binding sites identified in this study
compared with previous ChIP-chip and ChIP-seq approaches
(Gangwal et al. 2008; Guillon et al. 2009; Wei et al. 2010) likely
reflects greater sequencing depth and enhanced antibody sensi-
tivity. Since we examined targeting of transduced protein, which,
Figure 1. Experimental schema for lineage-specific transcription factor
silencing and expression. (A) Ewing Sarcoma (EWS502) cells and pri-
mary human endothelial cells (HUVEC) were transduced with lentivirus
expressing FLI1 39 UTR-directed shRNA and HA epitope-tagged versions
of EWS–FLI or FLI1. (B) Anti-FLI1 or anti-HA immunoblots of Ewing Sar-
coma cells (EWS502) or endothelial cells (HUVEC) demonstrating con-
current silencing and replacement with HA–EWS–FLI (EF) or HA–FLI1.
Tubulin serves as a loading control. Asterisks indicate where a background
band runs at a similar molecular weight as endogenous FLI1. (C ) After
EWS–FLI1 silencing alone (Knockdown) or together with ectopic EWS–
FLI1 or FLI1 expression, EWS502 cells were counted. EWS–FLI expression,




despite our efforts, varied somewhat from endogenous levels, it is
possible that aberrant targeting could be detected. However, despite
variation in expression and the use of different tumor cells, nearly
75% of the sites previously identified by ChIP-seq (Guillon et al.
2009) overlap the regions bound by EWS–FLI in this study.
Examination of specific genomic loci demonstrated the con-
tribution of chimerism and cell lineage to targeting (Fig. 2A,B). For
example, a site near NR0B1 previously shown to be occupied by
EWS–FLI (Kinsey et al. 2006; Gangwal and Lessnick 2008; Gangwal
et al. 2008; Garcia-Aragoncillo et al. 2008) was bound by EWS–FLI,
but not FLI1, in both cell types (Fig. 2C; Supplemental Fig. S2A). In
contrast, sites around the ephrin receptor, EPHA2, revealed a more
complex pattern, where common as well as transcription factor–
and cell type–specific sites were identified (Fig. 2D; Supplemental
Fig. S2B). Overall, in the tumor cells 46% of EWS–FLI sites over-
lapped FLI1 sites, whereas 75% of EWS–FLI sites overlapped with
FLI1 in HUVEC (Fig. 2A). Comparing targeting across cell types,
only ;50% of EWS–FLI or FLI1 binding sites were shared between
EWS502 and HUVEC (Fig. 2B).
We next examined the raw ChIP-seq signal over all genes to
compare the association of EWS–FLI and FLI with transcription and
genic regulatory elements (Fig. 2E). In tumor cells, the FLI1 signal
was greater at transcriptional start sites (TSS), in the proximal up-
stream region, and through the gene body compared with EWS–FLI.
Given the relative absence of EWS–FLI signal at these genic regions,
we compared the overall genomic distribution of binding sites (Fig.
2F). Again, in tumor cells FLI1 showed greater association with
promoters and 59 and 39 UTRs than EWS–FLI. Compared with FLI1,
EWS–FLI bound more frequently at distal intergenic regions (>60%
of sites). We observed only a slight skew toward intergenic binding
by EWS–FLI in endothelial cells. These data suggest that in both
cancer and normal cells, FLI1 more frequently targets gene-proxi-
mal sites, and chimerism leads to retargeting to intergenic regions.
However, chimerism-induced retargeting is significantly mitigated
by cell lineage.
EWS–FLI and FLI regulate divergent gene programs
To explore the transcriptional implications of genomic retargeting,
EWS–FLI and FLI1-associated gene expression changes were examined
using exon microarrays in both cell types. We identified differentially
regulated genes by comparing gene expression under conditions
of EWS–FLI or FLI1 knockdown only to knockdown with ectopic
transcription factor expression (Supplemental Table 3). Tran-
scriptional changes may be directly or indirectly related to ectopic
transcription factor expression. Although EWS–FLI occupied fewer
genomic sites than FLI1, it modulated the expression of three times
as many genes as FLI1 in tumor cells, though this skew was di-
minished in HUVEC (Supplemental Fig. S3A). Genes regulated by
FLI1 or EWS–FLI were mostly distinct (40%–45% shared in either
Figure 2. Chimerism alters ETS-mediated targeting. (A,B) Venn diagrams showing the number of unique and overlapping EWS–FLI and FLI1 binding
regions within the same cell type (A) or across cell types (B). (C,D) UCSC Genome Browser screenshots of EWS–FLI and FLI1 ChIP-seq signal at two genes:
NR0B1 (C ) and EPHA2 (D). Horizontal bars indicate targeted sites identified by ZINBA. Tag counts are shown in the y-axis. (E) Meta-gene profile of EWS–FLI
and FLI1 ChIP-seq reads; 1 kb upstream of the TSS through 1 kb downstream from transcriptional termination is represented. (F ) Percent overlap of ZINBA-
identified EWS–FLI and FLI1 binding sites with major functional genomic features. Genomic distribution of features (Genome) is shown for comparison.
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cell type). However, of the genes com-
monly modulated by both factors, 97%
were regulated concordantly in HUVEC,
whereas opposing effects on gene expres-
sion were frequently observed in tumor
cells (41% of coregulated genes) (Supple-
mental Fig. S3B). Cell type–specific regu-
lation was also evident. Only 34% of genes
modulated by EWS–FLI were shared across
the two cell types, whereas only 12% of
genes modulated by FLI1 were shared.
The classes of genes regulated by
EWS–FLI and FLI1 also differed signifi-
cantly (Supplemental Fig. S4). Approxi-
mately one-third of the genes modulated
by EWS–FLI in tumor cells were impli-
cated in cancer or cell cycle regulation; the
identification of these categories support
previous studies of gene regulation by
EWS–FLI (Riggi et al. 2005, 2008; Smith
et al. 2006; Kauer et al. 2009). In contrast,
FLI1 expression in tumor cells induced
genes associated with hematopoiesis,
hematological system development and
function, and cellular development, in-
cluding genes of the ephrin, thrombin,
and relaxin signaling pathways. In endo-
thelial cells, similar gene ontologies were
modulated by both transcription factors.
These data suggest that cell type greatly
influences the impact of chimerism on
transcriptional output.
Differentially targeted regions
are marked by DNA sequence
and regulatory variation
Since EWS–FLI and FLI1 binding sites were
mostly distinct, we hypothesized that ad-
ditional factors might specify EWS–FLI or
FLI1 targeting in a transcription factor– or
cell type–specific manner. We utilized hi-
erarchical clustering to identify binding
sites that most discriminated transcrip-
tion factor or cell type (Fig. 3A). Six major
clusters of binding sites emerged. These
clusters exhibited both transcription factor– and cell type–
dependence, with cell type being the primary determinant for the
majority of sites. Sites in clusters 1–3 exhibited greater binding in
tumor cells, whereas those in clusters 4–6 (representing 74% of the
sites) were enriched in endothelial cells. The finding of HUVEC-
specific clusters containing sites bound by both EWS–FLI and FLI1
further supports that in a normal cellular environment these tran-
scription factors share similar targeting.
Testing for associations between each cluster and gene ex-
pression demonstrated that sites in clusters 5 and 6 tended to be
located near differentially expressed genes from both cell types (Fig.
3B). Approximately 15% of differentially regulated genes contained
at least one of these sites within 25 kb. Furthermore, genes that
contained a TSS flanked by a site in clusters 5 or 6 (625 kb) were
significantly more likely to be modulated by EWS–FLI or FLI1 in
HUVEC (Fig. 3C). Genes harboring cluster 6 sites were frequently
up-regulated (82% and 88% for EWS–FLI and FLI1, respectively),
however, genes proximal to cluster 5 sites lacked this skew toward up-
regulation. Interestingly, these data suggest that although FLI1 tar-
gets sites in both clusters 5 and 6 equally, the potential for occupancy
of EWS–FLI at these sites characterizes elements that are functionally
distinct. Since the sequence composition of sites in clusters 5 and 6
were indistinguishable (see below), it is possible that chromatin dif-
ferences that permit EWS–FLI binding also favor enhancer activity.
Using the Genomic Regions Enrichment of Annotations Tool
(GREAT) (McLean et al. 2010), we observed that regions defined by
these clusters were strongly associated with specific biologically rel-
evant ontologies independent of our gene expression data (Supple-
mental Fig. S5; complete list in Supplemental Table 5). In support of
a direct regulatory role, EWS–FLI-specific binding sites (clusters 1 and
2) were significantly associated with genes regulated in cells engi-
neered to express EWS–FLI. Interestingly, cluster 2 sites (common to
Figure 3. Hierarchical clustering identifies cell and transcription factor–specific variation in genomic
targeting. (A) Hierarchical clustering of 6525 binding sites that exhibited the widest variation in signal
across transcription factors or cell types. Each row was median-centered and colored based on the
average read count across the region. (B) Distance (bp) from the transcriptional start site of the union set
of differentially expressed genes to the closet site from clusters 1–6. (C ) Number of EWS–FLI or FLI1
differentially expressed genes in HUVEC containing a cluster 5 (left) or cluster 6 (right) site within 25 kb of
its TSS, compared with 10,000 permutations of all RefSeq genes. (D) Normalized log2 ChIP-seq signal
around the midpoint of identified de novo transcription factor motifs derived from the sequences un-
derlying sites in each cluster. Clusters 1 and 2 were merged for the composite GGAA microsatellite motif
(1362 rows). Clusters 3–6 were merged for ETS (682 rows), ETS–AP1 (2780 rows), AP1 (1903 rows), and




both HUVEC and EWS502) were associated with genes involved in
mesodermal and craniofacial development, whereas sites in clusters
5 and 6 (specific for HUVEC) were largely associated with genes
known to play roles in vascular development, hypoxia response,
and HIF1A overexpression. These data corroborate our expression-
based gene ontology observations (Supplemental Fig. S4).
To identify other features of these differentially bound regions,
we performed de novo detection of over-represented motifs from
each cluster (Sharov and Ko 2009) and then matched these to known
motifs in TRANSFAC using TOMTOM (Matys et al. 2003). A total of
94% of sites in clusters 1 and 2, which exhibited an EWS–FLI-specific
pattern in the tumor cells, contained a tetranucleotide repeat har-
boring the core of the motif bound by ETS family members such as
FLI1 (Fig. 3D; see below). Sequence elements identified in clusters 3–
6 were more highly varied but commonly contained the canonical
ETS motif (see below).
Chimerism retargets EWS–FLI to tandem
tetranucleotide repeats
De novo motif detection on the sequences uniquely bound by EWS–
FLI in sarcoma cells (represented in clusters 1 and 2) identified
a GGAA-containing tetranucleotide microsatellite repeat. EWS–FLI
binding to these sequences had been observed in recent studies
(Gangwal et al. 2008; Guillon et al. 2009; Wei et al. 2010). The
number of tandem repeats bound by EWS–FLI was higher than
expected by chance in both cell types, although tumor cells dem-
onstrated greater enrichment (Fig. 4A). Examination of perfect se-
quential repeats revealed maximum enrichment at ;14 tandem el-
ements. Periodicity in the length of enriched repeats was observed
with a preference for 8, 12, and 14 repeat units. GGAA-containing
repeats, as annotated by RepeatMasker, which were bound by EWS–
FLI in EWS502, were significantly longer than those not bound,
with a median length of 100 bp (Fig. 4B). The difference in lengths
reflects the analysis of either perfect (Fig. 4A) or imperfect (Fig. 4B)
repeats. Unexpectedly, FLI1 also bound these repeats, although with
much lower frequency in both cell types, suggesting that the ability
to target these sites is not exclusive to EWS–FLI but rather reflects
the enhancement of a native characteristic.
We directly compared the binding of EWS–FLI and other fu-
sions characteristic of Ewing Sarcoma at sites containing either the
tetranucleotide repeat or the canonical high-affinity ETS motif.
The EWS–ERG and FUS–ERG fusions (Sorensen et al. 1994; Shing
et al. 2003) were epitope tagged and expressed at similar levels to
Figure 4. EWS–ETS fusions target GGAA-containing microsatellite repeats. (A) Tandem GGAA repeats identified in EWS–FLI and FLI1 binding sites in
EWS502 and HUVEC were compared with those detected by 1000 permutations of the identical number of regions over the mappable genome,
maintaining chromosomal distribution. All lengths exceeding one repeat were significant to P < 0.0001. To permit plotting lengths for which the per-
muted value was zero, 0.1 was added to each observed and expected value. (B) The lengths of repeat regions annotated by RepeatMasker bound by EWS–
FLI in EWS502 were compared with those unbound in mappable regions of the genome. Regions bound by EWS–FLI contained significantly longer repeats
as measured by a t-test. (C ) ChIP–qPCR on chromatin isolated from EWS502 cells expressing the various Ewing Sarcoma fusions. Results are shown as
a percent of input control. Overall, greater binding is identified at EWS–FLI-bound regions near differentially expressed genes that contained GGAA repeats
(NR0B1, CAV1, GSTM4, JAK1, IGF1) compared with those that bound EWS–FLI but did not harbor a repeat (NKX2-2, KIF14, JAK1, CDKN1A, MDM2). Five
control repeat-containing regions are included, and error bars represent the standard error of three replicates. (Inset) Western blot showing exogenous
expression of HA–EWS–FLI, HA–FUS–ERG, and HA–EWS–ERG in EWS502 cells. Tubulin serves as a loading control.
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endogenous EWS–FLI in conjunction with EWS–FLI silencing in
EWS502 (Fig. 4C, inset). All fusion proteins tested demonstrated
a greater enrichment at sites containing tandem repeats than
canonical high-affinity ETS motifs (Fig. 4C; Supplemental Fig. S6).
These data corroborate EWS–ERG ChIP (Wei et al. 2010) and sup-
port the general property of TET–ETS fusions to occupy these ele-
ments in a chromatinized genomic context. Moreover, these data
suggest that repeat-containing sites are more likely to be bound
than the canonical sites.
In light of recent studies suggesting a length requirement for
microsatellite enhancer function (Gangwal and Lessnick 2008;
Gangwal et al. 2008), we examined EWS–FLI and FLI1 sites con-
taining five or more tandem repeats. Approximately 30% of re-
gions uniquely bound by EWS–FLI in either cell type contained
these long tandem repeats, and they were nearly undetected in
regions unique to FLI1 in either cell type (0.2% and 0.04% in EWS502
and HUVEC, respectively). In agreement with the previous studies,
we found that these EWS–FLI-bound GGAA repeats were more
proximally located to genes up-regulated by EWS–FLI (Supple-
mental Fig. S7); a similar trend was observed for FLI1-bound
repeats near genes induced by FLI1 (data not shown). FLI1 bound
more proximally to FLI1-modulated genes compared with EWS–
FLI around EWS–FLI-regulated genes (Supplemental Fig. S8; Sup-
plemental Table 4), suggesting that in the context of chromatin,
tetranucleotide repeats may function primarily as transcriptional
enhancers and can be located distally from genes.
We then asked whether the preference of EWS–FLI for tetranu-
cleotide repeats resulted from increases in repeat lengths in Ewing
Sarcoma cells. Repeat-length variation could result from repeat ex-
pansion and selection during tumor development. Previous studies
that examined a small number of randomly selected tetranucleotide
repeats failed to demonstrate a difference between tumor cells and
the reference genome (Gangwal et al. 2008; Guillon et al. 2009).
We compared the lengths of several tetranucleotide repeats occu-
pied by EWS–FLI in tumor cells with the same regions in HUVEC
and the reference genome (hg18). Regions amenable to evaluation
were limited due to the challenges inherent in primer design for
repetitive regions. However, a region, located in an intron of IGF1,
exhibited mono- or biallelic presence of a sequence longer than that
predicted by the reference genome in four of seven Ewing Sarcoma
cell lines (Supplemental Fig. S9A). Sequencing of this region from
EWS502 cells confirmed that the difference resulted from nine ad-
ditional repeats (Supplemental Fig S9B). Interestingly, we observed
an extremely faint band running at approximately the same molec-
ular size as the expanded region in the pooled endothelial cells. It is
thus possible that expansion (relative to the reference genome) rep-
resents the selection for an allelic variant present in the population.
Combinatorial DNA-binding motifs distinguish endothelial
cell-targeted sites
Canonical ETS motifs were identified in 72% of sites in cluster 3
(largely specific to FLI1 in tumor and endothelial cells) and in sites
in clusters 4–6 (specific to endothelial cells but bound by both tran-
scription factors). The presence of ETS motifs in cluster 3 demon-
strates that FLI1 retains the ability for context-dependent targeting
even in sarcoma cells. Strikingly, the motif for the AP1 complex was
detected at nearly the same frequency as ETS at clusters 3–6 sites.
Remarkably, of the sites containing a computationally derived AP1
motif, 76% overlapped binding sites of c-Jun, a member of the AP1
complex, detected by ChIP-seq in HUVEC (The ENCODE Project
Consortium 2004). In addition to isolated AP1 motifs, composite
ETS and AP1 motifs were observed at ;46% of the sites in clusters
3–6. We explored variation in the spacing between the ETS and AP1
motifs; ;25% of the sites revealed separation of 1 bp with spacing
increments of 2–10 bp, each accounting for an additional 9% to
12% of sites. The composite nature of this ETS–AP1 motif is sug-
gestive of cooperative binding at these sites. The GATA motif was
also observed in ;15% of sites from clusters 3–6. The ETS motif
found within these regions demonstrated context specific sequence
variation. ETS sites in isolation typically contained a C preceding the
GGAA core, matching the canonical ETS motif (Wei et al. 2010).
However, ETS motifs in composite sites with AP1 were preceded
by an A. Similar motif variation had been observed in the tandem
binding sites of ETS1 with RUNX1 (Hollenhorst et al. 2009).
Since clusters 3–6 contained a similar set of motifs, we next
compared the intensity, location, and specificity of binding at sites
(from Fig. 3A) that contained a specific motif (Fig. 3D). Tetranu-
cleotide repeats were preferentially and centrally bound by EWS–
FLI. In the tumor cells, FLI1 demonstrated a modest ability to in-
teract with some of these sites as previously noted (Fig. 4A). In
endothelial cells, the signal intensities and positions of FLI1 and
EWS–FLI were similar around ETS, ETS–AP1, AP1, and GATA motif-
containing sites. In the tumor cells, FLI1 bound these sites, although
with far less signal intensity, again demonstrating the tendency of
FLI1 to function normally in tumor cells. Since de novo motif iden-
tification may preclude detection of less common motifs, we exam-
ined signals from HUVEC around sites containing computationally
predicted motifs for MYC:MAX, NFKB, STAT, PPAR, HNF4A, and
CREB (Xie et al. 2009). Although these sites represented <1% of those
analyzed, similar patterns of EWS–FLI and FLI1 signal were detected
(Supplemental Fig. S10). All motif associations were lost when the
sites were permuted (Supplemental Fig. S11). These data suggest
a large network of cooperative interactions for FLI1 binding, most
frequently AP1 and GATA. Sites selective for EWS–FLI occupancy in
sarcoma cells were distinguished in function, location, and com-
position from those sites that characterize endothelial targeting.
Chromatin features distinguish microsatellite repeats
in Ewing Sarcoma
Since cell lineage dominated the variation in targeting of both
chimeric and parental transcription factors, we explored features
of chromatin configuration and histone modifications that could
underlie these differences. We performed ChIP-seq in Ewing Sar-
coma cells for histone marks associated with active (H3K4me1,
H3K4me2, and H3K4me3) or repressed (H3K27me3) chromatin
(Supplemental Tables 1, 6). We also performed Formaldehyde-
Assisted Isolation of Regulatory Elements coupled with next-gen-
eration sequencing (FAIRE-seq) to identify regions of nucleosome
depletion that characterize active regulatory elements (Supplemen-
tal Tables 1, 6). Consistent with other cell types, we found that both
methylation on H3K4 and FAIRE demonstrated a strong association
with gene expression, whereas H3K27me3 was inversely correlated
with transcription (Fig. 5A).
Deregulation of homeobox genes is a common attribute of
cancer (Cillo et al. 1999). We compared the histone methylation
patterns across the four HOX clusters to those from embryonic stem
cells and HUVEC (ENCODE Project Consortium 2004) (Supple-
mental Fig. S12A). Interestingly, at the HOXA cluster, we detected
a bivalent signal similar to that observed in embryonic stem cells
(Bernstein et al. 2006). At the other HOX clusters however, there
was an overall lack of H3K27me3 and enrichment for H3K4me2




specific for a set of homeobox genes, in contrast to differentiated
cells (e.g., HUVEC). Widespread activation across nearly all HOX
genes in each cluster may contribute to the dedifferentiated or more
stem-like state of Ewing Sarcomas. The loss of H3K27me3 signal was
not observed genome-wide (e.g., PAX2 and WNT3A loci) (Supple-
mental Fig. S12B).
We focused our analysis on regions containing the tetranu-
cleotide repeats since they represented the most prominent feature
distinguishing EWS–FLI targeting. Comparing chromatin structure
and histone methylation of the repeats in Ewing Sarcoma cells with
HUVEC and other cell lines assayed as part of the ENCODE con-
sortium, we observed that in virtually all cell types, repressive marks
were common at GGAA microsatellites (Fig. 5B; Supplemental Fig.
S13) and other repetitive elements (Mikkelsen et al. 2007; Meissner
et al. 2008; Ernst and Kellis 2010). In Ewing cells, however, strong
H3K4me1 and H3K4me2 signals flanked EWS–FLI-bound repeats
Figure 5. Deregulation of repetitive elements in Ewing Sarcoma. (A) Heatmap of normalized ChIP and FAIRE signal 63 kb around TSS ranked by gene
expression in Ewing cells. Color was assigned on a log2 scale of3 to 3 for ChIP and6 to2 for FAIRE. (B) Normalized ChIP and FAIRE signals around the
centers of GGAA repeats in five ENCODE cell lines (GM12878, black; HUVEC, red; K562, blue; NHEK, green; H1hESC, orange). Mapability of the un-
derlying DNA sequence is represented on a scale of 0 (ambiguous) to 1 (unique) and is plotted in gray. (C ) Normalized ChIP and FAIRE signals around the
centers of EWS–FLI-bound (left) or -unbound (right) GGAA repeats in Ewing Sarcoma cells. Mapability of the underlying DNA sequence is represented on
a scale of 0 (ambiguous) to 1 (unique) and is plotted in gray. (D) Enrichment of EWS–FLI-bound GGAA repeats for RNA polymerase II (left) and histone H3
(right) in Ewing cells (red) and HUVEC (blue), as assayed by ChIP–qPCR. All values are represented as the fold-change relative to the average of the negative
controls; fold-change values are centered on 1. Error bars represent the standard error from three technical replicates.
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compared with those that were not bound, although the proportion
of active histone marks that directly overlapped repeats was similar
to other cell types (Fig. 5C; Supplemental Fig. S13). Moreover,
EWS–FLI-bound sites were largely devoid of H3K27me3 and were
nucleosome depleted. Relative to HUVEC and control regions,
these sites were also bound by RNA polymerase II (Fig. 5D). To
confirm nucleosome depletion, we also performed pan-histone H3
ChIP, which demonstrated overall histone H3 depletion at several
sites (Fig. 5D). Intriguingly, other classes of repetitive elements were
also enriched by FAIRE, including SINEs, LINEs, and other types of
simple and microsatellite repeats (data not shown). Together, these
data support the utilization of the microsatellites as transcriptional
enhancers. We also observed a striking difference in DNA sequence-
encoded nucleosome occupancy between EWS–FLI and FLI1-bound
sites (Supplemental Fig. S14). Whereas FLI-bound sequences dem-
onstrated high nucleosome occupancy, a feature of regulatory ele-
ments in higher eukaryotes (Kaplan et al. 2009), this pattern was not
seen for EWS–FLI-bound regions, further supporting the unique
attributes of EWS–FLI targeted domains.
EWS–FLI targets enhancer like elements altering
and maintaining the local chromatin environment
In addition to analyzing microsatellite regions we also assessed
chromatin structure and histone modifications of each class of the
differentially targeted regions identified by hierarchical clustering
(Fig. 3A). These data further support that the chromatin around
Ewing-specific clusters (clusters 1 and 2) exhibit a pattern resembling
that of an enhancer element only in tumor cells (Fig. 6A). Con-
versely, the endothelial-specific clusters (clusters 4–6) show an
enhancer-like pattern unique to HUVEC. Distinct from the other
clusters, sites in cluster 3, which exhibited binding by FLI1 in both
cell types, were marked by H3K4me3. This chromatin signature
supports our initial analyses (Fig. 2) that FLI1-specific sites tend
to be located proximally to transcriptional start sites.
Since EWS–FLI-specific binding sites were normally nu-
cleosome occupied in HUVEC and other cells, we asked whether
EWS–FLI could alter nucleosome occupancy. EWS–FLI expres-
sion in HUVEC decreased nucleosome occupancy (indicated by
increased FAIRE enrichment) at some of the closed chromatin re-
gions, relative to control regions (Fig. 6B,C). Moreover, silencing of
EWS–FLI in tumor cells resulted in increased nucleosome occupancy
at all sites tested. These findings suggest that EWSR1 chimerism
confers nucleosome displacement activity. Continued EWS–FLI
expression is required for the maintenance of an open chro-
matin configuration at all sites tested.
Discussion
Lineage-specific outcomes are observed when chimeric transcrip-
tion factors are expressed in various cell types, suggesting a major
cell-specific influence on activity. One cell type may be permissive
for transformation, whereas other cells may not tolerate expres-
sion, resulting in growth arrest or apoptosis. Cellular factors that
influence activity may not be evident from studies of transcription
factor targeting limited to a single transcriptional regulator in a
single cell type.
Using an integrated genomic strategy to compare the oncopro-
tein EWS–FLI with its parental protein FLI1 in two relevant human
cell types, we were able to separate the influence of chimerism and
Figure 6. The EWS–FLI complex is capable of altering chromatin. (A) Normalized signals for H3K4me1 (black), H3K4me2 (red), H3K4me3 (blue),
H3K27me3 (green), and FAIRE (orange) from both EWS502 and HUVEC are plotted for the 2-kb region surrounding the summits of sites identified by
hierarchical clustering. (B) Change in FAIRE enrichment at EWS–FLI-bound GGAA repeats following EWS–FLI expression in HUVEC. All values are repre-
sented as fold-change relative to scrambled shRNA control. Error bars represent the standard error from three technical replicates. (C ) Change in FAIRE
enrichment at EWS–FLI-bound GGAA repeats following EWS–FLI silencing in EWS502. All values are represented as fold change relative to scrambled




cell type on genomic targeting and function. In tumor cells, chi-
merism resulted in genomic retargeting, with ;40% of EWS–FLI
binding sites containing a tetranucleotide repeat composed of the
core ETS motif. Although FLI1 can bind to these repeats, the ma-
jority of FLI1 sites contained the canonical ETS motif. In contrast,
in endothelial cells, targeting of both proteins demonstrated re-
markable similarity. EWS–FLI and FLI1 localized to sites containing
the canonical ETS motif as well AP1 and GATA motifs. Binding to
a number of other less-common DNA motifs suggests an extended
network of interacting cooperative transcription factors. Given the
abundance of ETS motif-containing sites in the genome, these
interactions likely regulate cell lineage-specific patterns of geno-
mic targeting. Although FLI1 can bind the tetranucleotide repeats
both in vivo and in vitro, it fails to show activity at these repeats in
reporter-based assays (Gangwal et al. 2008, 2010) suggesting that
FLI1 requires the cooperation of other sequence-specific transcrip-
tion factors to activate transcription. The association of ETS proteins
with AP1 had been observed (Bassuk and Leiden 1995; Rao et al.
1999; Verger et al. 2001), and the functional association of EWS–FLI
or FLI1 with AP1 and GATA1 has been demonstrated in cellular
transformation and hematopoietic development (Verger et al. 2001;
Kim et al. 2006; Stankiewicz and Crispino 2009). However, our
data also suggest selectivity in cooperating transcription factors.
Although studies of ETS1 identified cooperative binding with
RUNX1 (Hollenhorst et al. 2009) and PAX5 (Garvie et al. 2001),
neither relationship was evident in this study.
Differential targeting of EWS–FLI was influenced by chromatin
structure and histone modifications. EWS–FLI-bound microsatellite
regions in tumor cells that were atypically marked with an enhancer
like signature bound RNA polymerase II, and resided in nucleosome-
depleted regions. Our data suggest that through EWSR1 chimerism,
the EWS–FLI complex gained nucleosome modification activity and
is necessary to alter the local chromatin landscape, resulting in
nucleosome depletion or destabilization. However, the observation
of nucleosome depletion at repetitive regions suggests that other
factors may initially create a favorable chromatin arrangement per-
mitting EWS–FLI targeting, a question currently being explored. The
presence of RNA polymerase II suggests that these regions may be
transcribed, a feature recently shown to be common among human
epithelial cancers (Ting et al. 2011).
This ability of EWS–FLI to alter chromatin structure is similar
to that of FOXA1 or GATA4, which bind their cognate sites and
affect chromatin configuration (Cirillo et al. 1998, 2002; Carroll
et al. 2005, 2006; He et al. 2010; Hurtado et al. 2011). Since EWS–FLI
does not contain the conserved motif thought to be required for
core histone interactions, its activity may be mediated through the
recruitment of histone modifying enzymes.
Comparative chromatin immunoprecipitation and the
comprehensive identification of regulatory elements by FAIRE
offer strategies to identify regions of the genome that might play
a role in tumor development. One such example is the EWS–FLI-
bound tetranucleotide repeat near IGF1, which exhibited length
polymorphisms that may influence EWS–FLI targeting and gene
regulation. A correlation between expression and the length of the
repeat has been demonstrated for NR0B1 (Garcia-Aragoncillo et al.
2008). The identification of an extended tandem repeat proximal to
IGF1 may be of significance for disease development and treatment,
since EWS–FLI-mediated IGF1 expression and signaling has been
implicated in Ewing Sarcoma development (Scotlandi et al. 1996;
Herrero-Martin et al. 2009) and inhibition of IGF1 signaling is being
studied as a potential therapeutic strategy. Such polymorphisms
could arise de novo during tumor development or represent an allelic
selection in individuals. The observed selection for longer repeats
could represent a mechanism to augment target gene expression.
This study demonstrates the prospect of translational cancer
genomics. Targeting the chromatin-modifying activity of the EWS–
FLI complex could exploit the persistent ‘‘addiction’’ of the tumor to
aberrant transcription and represents a novel therapeutic approach.
Further work will be necessary to determine the functional signifi-
cance of polymorphisms or other mutations on disease susceptibility,
onset, progression, and treatment.
Methods
Cell culture
EWS502 were cultured in RPMI 1640 supplemented with 15% FBS
and HUVEC cells were cultured in Vasculife Basal Media (Lifeline
Technologies) supplemented with 10% FBS. Both cell lines were
maintained at standard growth conditions of 37°C and 5% CO2.
Lentiviral knockdown expression
A short hairpin region complementary to the 39 untranslated re-
gion of FLI1 (59-TGCCCATCCTGCACACTTACTTCAAGAGAGTA
AGTGTGCAGGATGGGCTTTTTTC-39 sense strand) together with
PCR-generated HA-tagged EWS–FLI and HA-tagged FLI1 were cloned
into pLL5.5 (Rubinson et al. 2003). Lentivirus was produced in
HEK293T cells as described (Rubinson et al. 2003). EWS502 or
HUVEC cells were infected with lentivirus in the presence of pol-
ybrene (6 mg/mL) for 3 h, after which the medium was changed.
Chromatin or RNA was isolated at 72 h (see below).
Chromatin immunoprecipitation (ChIP) and Formaldehyde-
Assisted Isolation of Regulatory Elements (FAIRE)
Chromatin was isolated and immunoprecipitation was performed
as described in Davis et al. (2006) using 2 mg of anti-HA antibody
(Abcam ab9110), anti-H3K4me1 (Abcam ab8895), anti-H3K4me2
(Abcam ab32356), anti-H3K4me3 (Abcam ab12209), anti-H3K27me3
(Millipore 07-449), anti-POLR2A (RNA pol II) (Abcam ab103968), or
H3 (kindly provided by the Strahl lab). Immunoprecipitated DNAwas
prepared for high-throughput sequencing per the manufacturer’s
recommendations (Illumina), including DNA purification using
AMPure XP beads (Agencourt) before PCR amplification. Quanti-
tative PCR was performed as described (Absolute SYBR Green ROX
Mix, Thermo Scientific). PCR primers are available upon request.
FAIRE was performed on three independent cell harvests as pre-
viously described (Giresi et al. 2007), and isolated DNA was pre-
pared for sequencing as above.
Quality control and reference genome alignment
Reads from chromatin immunoprecipitations were aligned to the
reference human genome (hg18) with Bowtie (Langmead et al.
2009) using default parameters, and unambiguously placed reads
were retained. Biological replicates were then merged, cross-repli-
cate correlation was assessed, and reads were extended in silico to
a final length of 200 bp. Any extended reads that overlapped large-
scale repetitive elements were then removed. Reads from FAIRE
were allowed to potentially map to up to four genomic locations,
but the best scoring alignment was chosen. Biological replicates
were then merged, cross-replicate correlation was assessed, and
reads were extended in silico to a final length of 134 bp. Any ex-
tended reads that overlapped large-scale repetitive elements were
then removed.
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Peak calling, permutation, and repeat analysis
Areas of significant enrichment were identified using the Zero
Inflated Negative Binomial Algorithm (Rashid et al. 2011). A win-
dow size and offset of 250 and 50 bp, respectively, were utilized for
FLI1 and 500 and 125 bp for EWS–FLI. In all cases, a mixture re-
gression model was created using a combination of the input con-
trol, GC content, and a background-derived copy-number variation
model. Windows with q-values exceeding 0.95–0.99 were con-
sidered statistically significant, and peak boundaries were further
refined when necessary. Additional parameters were specified to
account for the broad nature of H3K27me3 domains. The per-
centage of peaks and average signal over a meta-gene were cal-
culated using CEAS (Shin et al. 2009) and plotted in R. GGAA
repeat regions were derived from RepeatMasker classes (GGAA)n,
(TTCC)n, (GA)n, (TC)n, or other simple repeats that contained
GGAA or its complement. For analyses of GGAA repeat length, peak
coordinates were permuted 1000 times across the uniquely map-
pable genome while maintaining chromosomal distribution using
BEDTools (Quinlan and Hall 2010). The frequency of tandem GGAA/
TTCC repeats was computed for lengths 1–25 and compared with
that of the test peak coordinates to compute a two-sided P-value.
Hierarchical clustering and motif identification
A union set of all EWS–FLI and FLI1 peaks for each cell type were
merged using Galaxy (Goecks et al. 2010). For each of the 51,085
regions, we retrieved the average number of sequencing reads from
each experiment and filtered for regions where the standard de-
viation and interquartile range exceeded 0.75 and 0.5, respectively.
The resulting 6525 regions were median centered and hierarchi-
cally clustered using average linkage and Pearson correlation. The
resulting dendrogram and heatmap were created in Java Treeview
(Saldanha 2004). Regions identified by clustering analysis were
narrowed to a refined window immediately around the location of
binding by intersecting the union set of all 200-bp windows around
the site of greatest signal (summit). De novo motif detection was
performed with CisFinder (Sharov and Ko 2009) using the 200-bp
flanking sequence as background. Motif heatmaps were created by
calculating the input-normalized number of sequencing reads for
each sample in the 2-kb region surrounding each identified motif
location.
Microarray analysis and gene permutation
RNA was extracted from ;1.5 3 107 lentivirally infected EWS502 and
HUVEC cells (RNeasy, Qiagen). After quality assessment (Bioanalyzer,
Agilent) RNA was hybridized to Affymetrix GeneChip Human Exon
1.0 ST arrays by the UNC Microarray Facility. Differentially expressed
genes were determined by an ANOVA (Partek Genomics Suite, P <
0.05) comparing gene expression under conditions of EWS–FLI or
FLI1 knockdown only to knockdown with ectopic transcription fac-
tor expression. Only genes with a RefSeq identification number that
mapped to standard chromosomes were considered. Differentially
expressed genes were assessed for significantly enriched biological
pathways and functions using Ingenuity Pathway Analysis (P < 0.05).
To compare the number of differentially expressed genes close to
binding sites as identified by hierarchical clustering to an expected
distribution, we permuted over all RefSeq genes 10,000 times and
computed a two-sided P-value accordingly.
Data access
All sequencing and microarray data have been submitted to the NCBI
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE31838.
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